Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has shared an update.
Fusen Pharmaceutical Co., Ltd. announced that its Metformin Empagliflozin Tablets were selected in the eleventh batch of China’s National Centralised Medicines Procurement. This selection is a significant development for the company, potentially enhancing its market position and offering growth opportunities in the Chinese pharmaceutical market.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company, along with its subsidiaries, focuses on the production and distribution of pharmaceutical products.
Average Trading Volume: 2,167,191
Technical Sentiment Signal: Hold
Current Market Cap: HK$514.7M
For a thorough assessment of 1652 stock, go to TipRanks’ Stock Analysis page.